Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		64 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Condensed Consolidated Statements of Operations [Abstract]
Grant awards		$ 3,110		$ 3,110	$ 585,589
Operating expenses:
Research and development	992,360	242,220	2,121,628	591,395	5,479,110
Clinical and regulatory	230,924	52,861	747,915	199,980	1,175,758
General and administration	737,540	227,209	1,443,856	813,660	3,739,382
Total operating expenses	1,960,824	522,290	4,313,399	1,605,035	10,394,250
Loss from operations	(1,960,824)	(519,180)	(4,313,399)	(1,601,925)	(9,808,661)
Interest income	500		502		1,189
Other income (expense)	(28,229)	246	(78,191)	774	(86,974)
Interest expense	(40,639)	(61,755)	(100,780)	(77,369)	(320,241)
Total non-operating expenses	(68,368)	(61,509)	(178,469)	(76,595)	(406,026)
Loss from continuing operations	(2,029,192)	(580,689)	(4,491,868)	(1,678,520)	(10,214,687)
Loss from discontinued operations		1,750		(18,379)	(288,724)
Net loss	(2,029,192)	(578,939)	(4,491,868)	(1,696,899)	(10,503,411)
Net loss - non-controlling interest	(61,750)	(11,130)	(139,796)	(25,508)	(216,057)
Beneficial conversion charge			(2,300,000)		(2,300,000)
Preferred Stock Dividend	(361,668)		(361,668)		(361,668)
Net loss attributable to common stockholders	$ (2,329,110)	$ (567,809)	$ (7,013,740)	$ (1,671,391)	$ (12,949,022)
Net loss per share attributable to common stockholders-basic and diluted	$ (0.48)	$ (0.31)	$ (2.45)	$ (0.91)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted	4,835,582	1,832,766	2,863,310	1,830,593